Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment

被引：32
|
作者：
Gilliam, Bruce L. [1 ]
Heredia, Alonso [1 ]
DeVico, Anthony [1 ]
Le, Nhut [1 ]
Bamba, Douty [1 ]
Bryant, Joseph L. [1 ]
Pauza, C. David [1 ]
Redfield, Robert R. [1 ]
机构：
[1] Univ Maryland, Sch Med, Inst Human Virol, Baltimore, MD 21201 USA
来源：
AIDS | 2007年 / 21卷 / 15期
关键词：
D O I：
10.1097/QAD.0b013e3282f02a4f
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
G1 cytostatic drugs reduce CCR5 co-receptor expression and enhance the antiviral activity of a CCR5 antagonist in vitro. The administration of rapamycin, a G1 cytostatic agent, to three cynomolgous macaques led to decreased CCR5 messenger RNA expression in peripheral blood mononuclear cells and cervicovaginal tissue. These results support further clinical evaluation of G1 cytostatic agents such as rapamycin targeting the downregulation of CCR5 expression as a strategy for both the prevention and treatment of HIV infection.
引用
收藏
页码：2108 / 2110
页数：3
相关论文
共 50 条
  • [41] HIV-1 infection in an individual homozygous for the CCR5 deletion allele
    Biti, R
    French, RF
    Young, J
    Bennetts, B
    Stewart, G
    Liang, T
    NATURE MEDICINE, 1997, 3 (03) : 252 - 253
  • [42] Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor
    Espy, Nicole
    Pacheco, Beatriz
    Sodroski, Joseph
    VIROLOGY, 2017, 508 : 90 - 107
  • [43] Allosteric regulation of CCR5 by guanine nucleotides and HIV-1 envelope
    Staudinger, R
    Wang, XH
    Bandrés, JC
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 286 (01) : 41 - 47
  • [44] HIV-1与CCR5受体关系研究概况
    宋娜丽
    云南中医中药杂志, 2012, 33 (10) : 64 - 66
  • [45] Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES
    Vanessa Nardese
    Renato Longhi
    Simona Polo
    Francesca Sironi
    Cinzia Arcelloni
    Rita Paroni
    Claudio DeSantis
    Paolo Sarmientos
    Menico Rizzi
    Martino Bolognesi
    Vincenzo Pavone
    Paolo Lusso
    Nature Structural Biology, 2001, 8 : 611 - 615
  • [46] HIV-1 infection in a man homozygous for CCR5 Delta 32
    OBrien, TR
    Winkler, C
    Dean, M
    Nelson, JAE
    Carrington, M
    Michael, NL
    White, GC
    LANCET, 1997, 349 (9060): : 1219 - 1219
  • [47] Vicriviroc, a CCR5 receptor antagonist for the potential treatment of HIV infection
    Klibanov, Olga M.
    CURRENT OPINION IN INVESTIGATIONAL DRUGS, 2009, 10 (08) : 845 - 859
  • [48] Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection - II.
    Meurer, LC
    Finke, PE
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Springer, MS
    Schleif, WA
    Carella, A
    Carver, G
    Holmes, K
    Emini, EA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U24 - U24
  • [49] Discovery of potent human CCR5 antagonists for the treatment of HIV-1 infection - IV.
    Caldwell, CG
    Chen, P
    Donnelly, KF
    Finke, PE
    Shankaran, K
    Meurer, LC
    Oates, B
    MacCoss, M
    Mills, SG
    Malkowitz, L
    Springer, MS
    Carella, A
    Carver, G
    Holmes, K
    Emini, EA
    Schleif, WA
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2000, 219 : U24 - U24
  • [50] Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5Δ32
    Benkirane, M
    Jin, DY
    Chun, RF
    Koup, RA
    Jeang, KT
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (49) : 30603 - 30606
12345